Trials / Withdrawn
WithdrawnNCT02769091
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
A 24-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of 80 mg TEV-45478 Once Daily as Treatment in Adult Patients With Nonalcoholic Steatohepatitis (NASH) Who Also Have Type 2 Diabetes Mellitus - GN
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect of TEV-45478, as compared with placebo, on liver health and liver fat content in patients with T2DM who also have Nonalcoholic Steatohepatitis (NASH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TEV-45478 | 80 mg (2x40mg) tablets once daily for up to 24 weeks |
| DRUG | Placebo |
Timeline
- Start date
- 2016-09-30
- Primary completion
- 2018-01-31
- Completion
- 2018-02-28
- First posted
- 2016-05-11
- Last updated
- 2021-11-09
Source: ClinicalTrials.gov record NCT02769091. Inclusion in this directory is not an endorsement.